Assessing the severity of atopic dermatitis in clinical trials and practice

被引:62
作者
Chopra, Rishi [1 ]
Silverberg, Jonathan, I [2 ,3 ]
机构
[1] Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Northwestern Univ, Dept Dermatol Prevent Med & Med Social Sci, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Northwestern Med Multidisciplinary Eczema Ctr, Chicago, IL 60611 USA
关键词
QUALITY-OF-LIFE; CORE OUTCOME MEASURES; ECZEMA AREA; INTERNATIONAL CONSENSUS; OBJECTIVE SCORAD; DISEASE SEVERITY; INDEX EASI; CYCLOSPORINE; VALIDATION; PATIENT;
D O I
10.1016/j.clindermatol.2018.05.012
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
There is a tremendous need for accurate and reproducible scoring systems for the grading of skin disease to further the development of research and standards of care. There are presently greater than 60 measures that have been used to assess the severity of atopic dermatitis. These assessments vary considerably with respect to content, scale, instructions, validity, and concordance. This contribution reviews the available scoring systems of atopic dermatitis signs based on their design and merit in specific settings. These scores assess lesional intensity and/or extent, symptoms, disease course, and epidermal function. Scoring atopic dermatitis, Investigator Global Assessment, and Eczema Area and Severity Index are the most commonly used assessments of atopic dermatitis signs. Eczema Area and Severity Index has emerged as the preferred outcome measure of atopic dermatitis signs for use in clinical trials. Unfortunately, Eczema Area and Severity Index can be cumbersome in clinical practice. Itch intensity (visual analog or numeric rating scales) and Patient-Oriented Eczema Measure have emerged as the preferred patient-reported outcome in clinical trials. Clinicians' gestalt global assessment of severity, Patient-Oriented Eczema Measure, and intensity of itch may be feasible for clinical practice. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:606 / 615
页数:10
相关论文
共 50 条
  • [1] ABRAMS BB, 1989, ACTA DERM-VENEREOL, P15
  • [2] QUANTIFICATION OF THE EXTENT AND THE SEVERITY OF ATOPIC-DERMATITIS - THE ADASI SCORE
    BAHMER, FA
    SCHAFER, J
    SCHUBERT, HJ
    [J]. ARCHIVES OF DERMATOLOGY, 1991, 127 (08) : 1239 - 1240
  • [3] Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme
    Barbier, N
    Paul, C
    Luger, T
    Allen, R
    De Prost, Y
    Papp, K
    Eichenfield, LF
    Cherill, R
    Hanifin, J
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2004, 150 (01) : 96 - 102
  • [4] Cyclosporine in severe childhood atopic dermatitis: A multicenter study
    BerthJones, J
    Finlay, AY
    Zaki, I
    Tan, B
    Goodyear, H
    LewisJones, S
    Cork, MJ
    Bleehen, SS
    Salek, MS
    Allen, BR
    Friedmann, P
    Harper, J
    Camp, RDR
    Smith, S
    GrahamBrown, RAC
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1996, 34 (06) : 1016 - 1021
  • [5] Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis
    BerthJones, J
    GrahamBrown, BAC
    Marks, B
    Camp, RDR
    English, JSC
    Freeman, K
    Holden, CA
    Rogers, SCF
    Oliwiecki, S
    Friedmann, PS
    LewisJones, MS
    Archer, CB
    Adriaans, B
    Douglas, WS
    Allen, BR
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1997, 136 (01) : 76 - 81
  • [6] Boers M, 1998, J RHEUMATOL, V25, P198
  • [7] The burden of atopic dermatitis: Impact on the patient, family, and society
    Carroll, CL
    Balkrishnan, R
    Feldman, SR
    Fleischer, AB
    Manuel, JC
    [J]. PEDIATRIC DERMATOLOGY, 2005, 22 (03) : 192 - 199
  • [8] Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)
    Chalmers, J. R.
    Simpson, E.
    Apfelbacher, C. J.
    Thomas, K. S.
    von Kobyletzki, L.
    Schmitt, J.
    Singh, J. A.
    Svensson, A.
    Williams, H. C.
    Abuabara, K.
    Aoki, V.
    Ardeleanu, M.
    Awici-Rasmussen, M.
    Barbarot, S.
    Berents, T. L.
    Block, J.
    Bragg, A.
    Burton, T.
    Clemmensen, K. K. Bjerring
    Creswell-Melville, A.
    Dinesen, M.
    Drucker, A.
    Eckert, L.
    Flohr, C.
    Garg, M.
    Gerbens, L. A. A.
    Graff, A. L. B.
    Hanifin, J.
    Heinl, D.
    Humphreys, R.
    Ishii, H. A.
    Kataoka, Y.
    Leshem, Y. A.
    Marquort, B.
    Massuel, M. -A.
    Merhand, S.
    Mizutani, H.
    Murota, H.
    Murrell, D. F.
    Nakahara, T.
    Nasr, I.
    Nograles, K.
    Ohya, Y.
    Osterloh, I.
    Pander, J.
    Prinsen, C.
    Purkins, L.
    Ridd, M.
    Sach, T.
    Schuttelaar, M. -L. A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 (01) : 69 - 79
  • [9] Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)
    Chalmers, J. R.
    Schmitt, J.
    Apfelbacher, C.
    Dohil, M.
    Eichenfield, L. F.
    Simpson, E. L.
    Singh, J.
    Spuls, P.
    Thomas, K. S.
    Admani, S.
    Aoki, V.
    Ardeleanu, M.
    Barbarot, S.
    Berger, T.
    Bergman, J. N.
    Block, J.
    Borok, N.
    Burton, T.
    Chamlin, S. L.
    Deckert, S.
    DeKlotz, C. C.
    Graff, L. B.
    Hanifin, J. M.
    Hebert, A. A.
    Humphreys, R.
    Katoh, N.
    Kisa, R. M.
    Margolis, D. J.
    Merhand, S.
    Minnillo, R.
    Mizutani, H.
    Nankervis, H.
    Ohya, Y.
    Rodgers, P.
    Schram, M. E.
    Stalder, J. F.
    Svensson, A.
    Takaoka, R.
    Teper, A.
    Tom, W. L.
    von Kobyletzki, L.
    Weisshaar, E.
    Zelt, S.
    Williams, H. C.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (06) : 1318 - 1325
  • [10] Outcome measures of disease severity in atopic eczema
    Charman, C
    Williams, H
    [J]. ARCHIVES OF DERMATOLOGY, 2000, 136 (06) : 763 - 769